Re: See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostatic cancer. Eur Urol 2003;44:512-8

Eur Urol. 2004 May;45(5):674; author reply 674-5. doi: 10.1016/j.eururo.2004.01.006.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Anilides / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Chemotherapy, Adjuvant
  • Disease Progression
  • Humans
  • Male
  • Nitriles
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Time Factors
  • Tosyl Compounds

Substances

  • Anilides
  • Antineoplastic Agents
  • Nitriles
  • Tosyl Compounds
  • bicalutamide
  • Prostate-Specific Antigen